COLORADO SPRINGS, Colo.,
July 10, 2013 /PRNewswire/ -- The
X-Change Corporation (NASDAQ OTC: XCHC), a U.S. Company
specializing in cannabinoid formulation-based health and wellness
solutions, in a strategic growth initiative announces advanced
negotiations regarding multiple product distribution licensing and
management agreements spanning seven states across America,
including Colorado, Nevada, California, Illinois, Massachusetts, Arizona, and Washington State. As previously announced, the
Company already has several proprietary cannabinoid products and
formulations ready for release through dispensaries, organic
breeding facilities, secondary product distribution centers,
confidentiality-protected patient-doctor tracking, and opt-in
patient studies.
The Company expects to sign and announce the first state
licensee for product licensing, distribution, and management
arrangements shortly, and plans to put in place activities to
implements these programs in compliance with each individual state
regulatory authority on a state-by-state basis.
The planned agreements are designed to establish and empower
licensees to produce and distribute the Company's cannabinoid-based
formulations, while collecting data and studying potential efficacy
in the seven chosen states as a first step toward entering the
legal state markets, with each state having is own core operating
unit to ensure individual state compliance and patient access.
Current scientific data suggest that unlike many modern drug
treatments, cannabis-based products potentially can be developed
into effective medications with outstanding safety profile.
As patients in the states with medical cannabis laws are allowed to
make safe, informed decisions to legally administer cannabis-based
preparations with physician recommendations for a variety of their
ailments, the Company is committed to collaborating with the
communities, their physicians and the regulators to obtain
peer-reviewed clinical data. Further, the Company intends to
support the establishment of confidential and privacy-sensitive,
opt-in, individual informed consent based tracking procedures for
patients and their doctors to promote the scientific documentation
of patient outcomes in an effort to advance the efficacy of patient
treatments.
The Company receives many requests and inquires daily from
individuals around the world looking for cannabis-based treatment
information and cannabis-extract based products for numerous
critical ailments. Today's announced growth plan is designed for
the Company to release its proprietary cannabinoid-based products
through the licensed partners in each of the states in which the
use of medical cannabis is legal as well as targeting markets in
other states with its hemp products, which are not categorized as
medical cannabis. Patient requests are increasingly diverse and
voluminous, consonant with the progress and growing acceptance of
potential for developing cannabinoid-based treatment for multiple
diseases including cancer, chronic pain, post traumatic stress
disorder (PTSD), influenza, HIV/AIDS, high blood pressure,
arthritis, Alzheimer's, anti-aging, autism, asthma, auto immune
disease, brain trauma (closed head injury), Crohn's disease,
irritable bowel syndrome (IBS), diabetes, digestive illnesses,
gastro intestinal reflux disease (GERD), glaucoma,
methicillin-resistant Staphylococcus aureus (MRSA), multiple
sclerosis (MS), and Tourette syndrome.
About The X-Change Corporation
The X-Change Corporation is currently developing new natural
cannabinoid containing products based on innovative formulations to
utilize the unique and potent benefits of the cannabis and hemp
plants. Medicinal properties of cannabis and hemp have been known
and applied for thousands of years. With the aid of
scientific research, The X-Change Corporation is translating such
knowledge into development of effective cannabinoid
formulation-based health and wellness solutions as well as
cosmeceutical, nutraceutical, and food brands throughout the world.
The Company's health and wellness, nutritional, and cosmetics lines
will address personal needs and will evolve with the introduction
of new formulations and products, advancing the Company within the
expanding multibillion-dollar global market.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
works such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. X-Change Corp. does not undertake any duty nor does it
intend to update the results of these forward-looking
statements.
X-Change Corp.
President
Dr. Dorothy Bray
info@xchangecorp.com
www.xchangecorp.com
+1.866.326.5595
Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development
rkane@xchangecorp.com
+1.561.420.4824
SOURCE The X-Change Corporation